Brown Advisory Reports 5.8% Of Bioventus Class A Shares In Client Holdings
The parent company reported voting authority over 3,797,325 shares, with the holdings belonging to investment companies and managed accounts.
Brown Advisory reported a 5.8% stake in Bioventus, which makes medical devices for pain relief and bone and joint treatment, in a passive ownership filing Friday. The parent company for investment advisers and a bank reported 3,960,468 Class A shares as of September 30.
Client Shares, Advisory Authority
The shares belong to investment companies and managed accounts served by Brown Advisory's subsidiaries. Their advisory agreements give the subsidiaries authority to vote shares, make investment decisions or both, which is why the advisers report beneficial ownership.
Brown Advisory reported sole voting authority over 3,797,325 shares. It certified that the securities were bought and held through ordinary business, without a purpose of changing or influencing Bioventus's control.
The Subsidiaries Behind The Position
Brown Advisory LLC, an investment adviser among the reporting subsidiaries, reported 3,906,329 shares, or 5.72% of Class A stock. Its sole voting authority covered 3,743,186 shares.
Brown Investment Advisory & Trust, the bank subsidiary, reported 48,503 shares and 0.07% of the class. The other reporting investment advisers were Signature Financial Management, with 2,375 shares, and Brown Advisory's United Kingdom subsidiary, with 3,261 shares.
Each of those smaller positions carried sole voting authority over all its reported shares. These are subsidiary-level disclosures within the parent's reported position.
Pain Relief And Bone Healing
Bioventus's products include knee injections using hyaluronic acid and implanted devices that stimulate nerves to treat pain. Its surgical business sells ultrasonic systems for cutting bone and bone graft products.
Restorative therapies include EXOGEN, an ultrasound device used to help fractures heal. Physicians use the company's products in their offices, surgery centers and hospitals.
The U.S. segment accounted for 88% of net sales in the fiscal year ended December 31, 2025, with International contributing 12%. Bioventus uses direct sales teams in the United States and a mix of direct and indirect teams and distributors abroad; most manufacturing takes place in Cordova, Tennessee.
Brown Advisory's reported 5.8% position covers Bioventus's Class A stock, with the underlying securities held for investment companies and managed accounts.